Nahdi Medical Company (TADAWUL:4164)
Saudi Arabia · Delayed Price · Currency is SAR 95.50
-0.75 (-0.78%)
Aug 13, 2026, 3:19 PM AST
Nahdi Medical Company Income Statement
Financials in millions SAR. Fiscal year is January - December.
Millions SAR. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 10,519 | 10,213 | 9,446 | 8,714 | 8,616 | 8,066 | |
Revenue Growth | 6.49% | 8.12% | 8.41% | 1.13% | 6.82% | -6.67% |
Cost of Revenue | 6,742 | 6,521 | 6,025 | 5,278 | 5,141 | 4,821 |
Gross Profit | 3,778 | 3,692 | 3,421 | 3,436 | 3,475 | 3,245 |
Selling, General & Admin | 2,888 | 2,786 | 2,577 | 2,499 | 2,500 | 2,397 |
Other Operating Expenses | -11.11 | -19.79 | -27.91 | -23.7 | -24.3 | -58.06 |
Operating Expenses | 2,877 | 2,766 | 2,549 | 2,475 | 2,475 | 2,339 |
Operating Income | 901.03 | 926.06 | 871.66 | 960.74 | 999.82 | 905.94 |
Interest Expense | -86.54 | -88.01 | -73.72 | -50.46 | -50.47 | -78.88 |
Interest & Investment Income | 37.32 | 48.76 | 50.8 | 56.82 | 12.13 | 2.96 |
Currency Exchange Gain (Loss) | 11.37 | 11.37 | 8.34 | 7.91 | 1.8 | - |
Other Non Operating Income (Expenses) | -52.2 | -52.75 | -25.67 | -31.47 | -11.15 | 7.61 |
EBT Excluding Unusual Items | 810.98 | 845.42 | 831.41 | 943.53 | 952.13 | 837.63 |
Gain (Loss) on Sale of Assets | 0.49 | 0.49 | 1.54 | 0.22 | -17.37 | 0.15 |
Asset Writedown | - | - | 1.6 | 0.5 | 3.16 | 19.49 |
Pretax Income | 816.59 | 845.91 | 834.54 | 944.25 | 937.93 | 857.27 |
Income Tax Expense | 28.51 | 15.17 | 13.82 | 51.63 | 50.11 | 44.74 |
Net Income | 788.08 | 830.74 | 820.72 | 892.62 | 887.81 | 812.53 |
Net Income to Common | 788.08 | 830.74 | 820.72 | 892.62 | 887.81 | 812.53 |
Net Income Growth | -5.46% | 1.22% | -8.05% | 0.54% | 9.26% | -4.31% |
Shares Outstanding (Basic) | 130 | 130 | 130 | 130 | 130 | 130 |
Shares Outstanding (Diluted) | 130 | 130 | 130 | 130 | 130 | 130 |
Shares Change | - | - | - | - | - | - |
EPS (Basic) | 6.06 | 6.39 | 6.31 | 6.87 | 6.83 | 6.25 |
EPS (Diluted) | 6.06 | 6.39 | 6.31 | 6.87 | 6.83 | 6.25 |
EPS Growth | -5.46% | 1.22% | -8.05% | 0.54% | 9.26% | -4.31% |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 1,175 | 746.64 | 1,152 | 962.17 | 1,418 | 1,051 |
Free Cash Flow Per Share | 9.04 | 5.74 | 8.86 | 7.40 | 10.90 | 8.09 |
Dividend Per Share | 6.000 | 5.600 | 5.500 | 5.500 | 5.310 | - |
Dividend Growth | 7.14% | 1.82% | 0% | 3.58% | - | - |
Gross Margin | 35.91% | 36.15% | 36.21% | 39.43% | 40.33% | 40.23% |
Operating Margin | 8.57% | 9.07% | 9.23% | 11.03% | 11.60% | 11.23% |
Profit Margin | 7.49% | 8.13% | 8.69% | 10.24% | 10.30% | 10.07% |
Free Cash Flow Margin | 11.17% | 7.31% | 12.19% | 11.04% | 16.45% | 13.04% |
EBITDA | 1,199 | 1,215 | 1,130 | 1,181 | 1,192 | 1,070 |
EBITDA Margin | 11.40% | 11.90% | 11.96% | 13.55% | 13.84% | 13.26% |
D&A For EBITDA | 298.17 | 289.25 | 258.31 | 219.86 | 192.36 | 164.03 |
EBIT | 901.03 | 926.06 | 871.66 | 960.74 | 999.82 | 905.94 |
EBIT Margin | 8.57% | 9.07% | 9.23% | 11.03% | 11.60% | 11.23% |
Effective Tax Rate | 3.49% | 1.79% | 1.66% | 5.47% | 5.34% | 5.22% |
Advertising Expenses | - | 52.94 | 59.61 | 66.36 | 67.81 | 54.92 |